These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 29961771)

  • 1. Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION).
    Luu M; Benzenine E; Doret M; Michiels C; Barkun A; Degand T; Quantin C; Bardou M
    Am J Gastroenterol; 2018 Nov; 113(11):1669-1677. PubMed ID: 29961771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study.
    Chaparro M; Verreth A; Lobaton T; Gravito-Soares E; Julsgaard M; Savarino E; Magro F; Biron AI; Lopez-Serrano P; Casanova MJ; Gompertz M; Vitor S; Arroyo M; Pugliese D; Zabana Y; Vicente R; Aguas M; Shitrit BA; Gutierrez A; Doherty GA; Fernandez-Salazar L; Cadilla MJ; Huguet JM; OʼToole A; Stasi E; Marcos MN; Villoria A; Karmiris K; Rahier JF; Rodriguez C; Palomares DM; Fiorino G; Benitez JM; Principi M; Naftali T; Taxonera C; Mantzaris G; Sebkova L; Iade B; Lissner D; Bradley FI; Roman LA; Marin-Jimenez I; Merino O; Sierra M; Van Domselaar M; Caprioli F; Guerra I; Peixe P; Piqueras M; Rodriguez-Lago I; Ber Y; van Hoeve K; Torres P; Gravito-Soares M; Rudbeck-Resdal D; Bartolo O; Peixoto A; Martin G; Armuzzi A; Garre A; Donday MG; de Carpi MFJ; Gisbert JP
    Am J Gastroenterol; 2018 Mar; 113(3):396-403. PubMed ID: 29460920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation.
    Duricova D; Dvorakova E; Hradsky O; Mitrova K; Durilova M; Kozeluhova J; Kohout P; Zarubova K; Bronsky J; Hradska N; Bronska E; Adamcova M; Machkova N; Hruba V; Bortlik M; Lukas M; Malickova K; Lukas M
    Inflamm Bowel Dis; 2019 Mar; 25(4):789-796. PubMed ID: 30239799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety.
    de Lima A; Zelinkova Z; van der Ent C; Steegers EA; van der Woude CJ
    Gut; 2016 Aug; 65(8):1261-8. PubMed ID: 25966992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.
    Mozaffari S; Abdolghaffari AH; Nikfar S; Abdollahi M
    Hum Exp Toxicol; 2015 May; 34(5):445-59. PubMed ID: 25378092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system.
    Wieringa JW; Driessen GJ; Van Der Woude CJ
    Expert Rev Gastroenterol Hepatol; 2018 Aug; 12(8):811-818. PubMed ID: 29972674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
    Kanis SL; Modderman S; Escher JC; Erler N; Beukers R; de Boer N; Bodelier A; Depla ACTM; Dijkstra G; van Dijk ARM; Gilissen L; Hoentjen F; Jansen JM; Kuyvenhoven J; Mahmmod N; Mallant-Hent RC; van der Meulen-de Jong AE; Noruzi A; Oldenburg B; Oostenbrug LE; Ter Borg PCJ; Pierik M; Romberg-Camps M; Thijs W; West R; de Lima A; van der Woude CJ;
    Gut; 2021 Jul; 70(7):1266-1274. PubMed ID: 33046558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.
    Androulakis I; Zavos C; Christopoulos P; Mastorakos G; Gazouli M
    World J Gastroenterol; 2015 Dec; 21(47):13205-11. PubMed ID: 26715803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-α during pregnancy: A systemic review and meta-analysis.
    Barenbrug L; Groen MT; Hoentjen F; van Drongelen J; Reek JMPAVD; Joosten I; de Jong EMGJ; van der Molen RG
    J Autoimmun; 2021 Aug; 122():102676. PubMed ID: 34126302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.
    Bortlik M; Machkova N; Duricova D; Malickova K; Hrdlicka L; Lukas M; Kohout P; Shonova O; Lukas M
    Scand J Gastroenterol; 2013 Aug; 48(8):951-8. PubMed ID: 23834232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of first year vaccination in children born to mothers with inflammatory bowel disease and exposed in utero to anti-TNFα agents: a French nationwide population-based cohort.
    Luu M; Benzenine E; Barkun A; Doret M; Michiels C; Degand T; Quantin C; Bardou M
    Aliment Pharmacol Ther; 2019 Dec; 50(11-12):1181-1188. PubMed ID: 31617226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review.
    El Mourabet M; El-Hachem S; Harrison JR; Binion DG
    Curr Drug Targets; 2010 Feb; 11(2):234-41. PubMed ID: 19916950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.
    Julsgaard M; Christensen LA; Gibson PR; Gearry RB; Fallingborg J; Hvas CL; Bibby BM; Uldbjerg N; Connell WR; Rosella O; Grosen A; Brown SJ; Kjeldsen J; Wildt S; Svenningsen L; Sparrow MP; Walsh A; Connor SJ; Radford-Smith G; Lawrance IC; Andrews JM; Ellard K; Bell SJ
    Gastroenterology; 2016 Jul; 151(1):110-9. PubMed ID: 27063728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are anti-TNF drugs safe for pregnant women with inflammatory bowel disease?
    Brennan GT; Duong A; Nguyen ET; Nguyen DL
    Cleve Clin J Med; 2018 Dec; 85(12):923-924. PubMed ID: 30526752
    [No Abstract]   [Full Text] [Related]  

  • 17. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
    Matro R; Martin CF; Wolf D; Shah SA; Mahadevan U
    Gastroenterology; 2018 Sep; 155(3):696-704. PubMed ID: 29857090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease.
    Mahadevan U; Long MD; Kane SV; Roy A; Dubinsky MC; Sands BE; Cohen RD; Chambers CD; Sandborn WJ;
    Gastroenterology; 2021 Mar; 160(4):1131-1139. PubMed ID: 33227283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.
    Khan N; Asim H; Lichtenstein GR
    Expert Opin Drug Saf; 2014 Dec; 13(12):1699-708. PubMed ID: 25406728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effects of Active IBD During Pregnancy in the Era of Novel IBD Therapies.
    de Lima-Karagiannis A; Zelinkova-Detkova Z; van der Woude CJ
    Am J Gastroenterol; 2016 Sep; 111(9):1305-12. PubMed ID: 27349339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.